Founded in 2009, Remidio operates in Health Tech industry. Initially focusing on portable and affordable retinal imaging devices, the company has evolved to incorporate artificial intelligence in its ...
Funding stage:
Corporate Round
Last funding:
18/02/2023
Total funding:
$18.11 Mn+
Revenue:
Investors
Employee count:
224
Last 90d
224
Last 90d
Web traffic:
17.82K
17.82K
Last 30d
Last 30d
Glassdoor Rating:
Remidio: Cap Table Highlights
A snapshot of cap table and shareholder metrics
Total Shareholders32
Latest Filing Date16 March 2025- Funding Events42
Event-Based View
Event-Based detailed View by Filings
FAQs on Cap Table of Remidio
As of 17 March 2025, Remidio's equity is held by 30 shareholders, with the top three being Sun Pharma, Anand Sivaraman, and Montane Ventures.
Sun Pharma holds the largest stake in Remidio at 95.6% as of 17 March 2025.
As of 17 March 2025, founders collectively hold 1.3% equity in Remidio.
As of 17 March 2025, investors collectively hold 2.1% equity in Remidio.
Remidio's ESOP pool stands at 0.9% of total equity as of 17 March 2025.
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links